CMV reactivation post allogeneic stem cell transplantation decreases relapse risk and survival, and increases NRM – a single center analysis

= 0.13 vs. refractory). CMV reactivation was associated with lower relapse risk in patients with myeloid malignancy, although the biological basis of this association remains uncertain. Refractory CMV increases CMV-related mortality, but probable refractory CMV does not increase mortality risk.